Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

ne million men in the United States have prostate cancer, with an estimated 186,320 new cases expected to be diagnosed in 2008, and approximately 28,660 men expected to die this year from the disease. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

About Active Cellular Immunotherapy with PROVENGE

PROVENGE may represent the first product in a new class of active cellular immunotherapies (ACIs) that are uniquely designed to use live human cells to engage the patient's own immune system with the goal of eliciting a specific long-lasting response against cancer. In clinical studies, patients typically received three doses of PROVENGE over a one-month period as a complete course of therapy.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... , October 27, 2014 ... right to produce, exhibit and sell its artificial ... to impeach their patent.      (Photo: ... four years of fighting, the definitive judgement has ... and produces innovative and accessible hi-tech prostheses with ...
(Date:10/27/2014)... October 27, 2014 The “Molecular ... Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End ... Service, Software) - Global Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/27/2014)... The report “Smart Highway Market by ... Monitoring), and by Display (Variable Message Signs, Digital ... global market into various sub-segments with in-depth analysis ... drivers and restraints for this market with insights ... market tables and 37 figures spread through 141 ...
Breaking Biology Technology:CU Denver study says upgrading infrastructure could reduce flood damage 2Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4
... COLUMBIA, Md., May 22 Martek Biosciences,Corporation (Nasdaq: ... results,of its second quarter of fiscal 2008 on June ... the release, at 4:45 p.m. ET Martek will,conduct a ... quarter of,fiscal 2008 with investors. All interested parties may ...
... for profit, WASHINGTON, May 22 Medtronic ... to pay $75,000,000 to the federal government to,settle ... device,company,s sales and pricing strategy to increase its ... lawsuit, which the government joined, was,kept under seal ...
... Nektar,Therapeutics (Nasdaq: NKTR ) announced today ... as Chief Operating Officer and Head of the,PEGylation ... aspects of the PEGylation Business Unit, including research,and ... He will also,serve as Chairman of Nektar India ...
Cached Biology Technology:Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 2Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit 3
(Date:10/29/2014)... of its kind to date, researchers have used DNA ... risk for autism. Joseph Buxbaum, Ph.D., Icahn School of ... Ph.D., Broad Institute of Harvard and MIT, and their ... children, parents and unrelated people. They identified changes in ... risk for autism spectrum disorder (ASD) – a jump ...
(Date:10/29/2014)... Online registration is open for the ... Scientific Meeting. SIR 2015 is the one ... trainees and related health care professionals can ... image-guided science and technologies being presented, discussed ... community in minimally invasive, image-guided medicine, SIR ...
(Date:10/29/2014)... Plants rely on sunlight to make their food, but they ... do. Recently, scientists discovered a group of molecules in plants ... in the Journal of the American Chemical Society , ... plant sunscreens work. , Timothy Zwier and colleagues at Purdue ... to daily can cause serious damage to plant DNA and, ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... with a number of pathological conditions, including cancer. Publishing in ... in drinking water given at the maximum levels permitted ... in mice. On the other hand, reducing copper levels reduced ... essential factor for the growth of tumors in humans as ...
... Hall Institute have been awarded more than $2.2 million from ... disorders and inflammatory diseases. Three institute researchers - ... - were announced last week as recipients of ARC Future ... body controls errant immune cells that cause type 1 diabetes ...
... , Nov. 14, 2013  Based on its recent research ... presents Cognitec Systems GmbH with the 2013 European ... Cognitec,s blinkers-on focus on face biometrics earned the ... to develop its flagship face recognition technology, FaceVACS-VideoScan. ...
Cached Biology News:Copper intake makes tumors breathe 2ARC Future Fellows awarded $2.2M for immune and inflammation studies 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
... The DNA Engine Dyad instrument is the ... Featuring MJ's world-class thermal performance, the ... display, as well as point-and-click navigation via ... Dyad can be easily and economically expanded ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
ID clarifier: platform...
... Tetrad 2 thermal cycler accommodates a ... heat-pump assemblies), which hold different types ... computer drives an advanced graphical interface ... lid temperatures. Peltier heat pumps, built ...
Biology Products: